ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
January 16, 2025Innovent Biologics, Inc. announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343. -
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
December 09, 2024announced updated Phase 1 study results of IBI343, an innovative anti-Innovent BiologicsCLDN18.2 ADC, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) during an oral presentation at the ESMO Asia Congress 2024.
Pharma Sources Insight January 2025
